Filgrastim Recruiting Phase 2 Trials for Leukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02782546Cytokine Induced Memory-like NK Cell Adoptive Therapy After Haploidentical Donor Hematopoietic Cell Transplantation
NCT03356080DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess
NCT03045627Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML Patients
NCT02275663Azacytidine Plus FLAG for Relapsed or Refractory AML